StreetInsider.com News Articles

Lobe Sciences Announces Proposed Shares for Debt Transaction

Mon, 01 Jun 2026 22:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in outstanding management and director fee debt through the issuance of an aggregate of 12,749,643 common shares of the Company (the "Settlement Shares") at a price of $0.11 per Settlement Share (the "Debt

Lobe Sciences Announces Proposed Shares for Debt Transaction

Mon, 01 Jun 2026 22:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in outstanding management and director fee debt through the issuance of an aggregate of 12,749,643 common shares of the Company (the "Settlement Shares") at a price of $0.11 per Settlement Share (the "Debt

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York

Wed, 06 May 2026 20:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be attending the D. Boral Capital Global Conference being held on May 7, 2026 at The Plaza Hotel in New York City.
Dr. Sancilio will be available for meetings with institutional investors, pharmaceutical companies, and potential

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York

Wed, 06 May 2026 20:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be attending the D. Boral Capital Global Conference being held on May 7, 2026 at The Plaza Hotel in New York City.
Dr. Sancilio will be available for meetings with institutional investors, pharmaceutical companies, and potential

Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress

Wed, 06 May 2026 06:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced its unaudited interim financial results for the second quarter of fiscal 2026 ended February 28, 2026 ("Q2 2026") and provided an operational update.
During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined approach to capital allocation. Management believes the progress achieved in Q2 2026

Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress

Wed, 06 May 2026 06:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates through a disciplined pharmaceutical development platform, progressing assets from early development to the clinic through focused subsidiary companies, today announced its unaudited interim financial results for the second quarter of fiscal 2026 ended February 28, 2026 ("Q2 2026") and provided an operational update.
During the quarter, the Company continued to advance its development pipeline while maintaining a disciplined approach to capital allocation. Management believes the progress achieved in Q2 2026

Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders

Thu, 23 Apr 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, welcomes the recent White House Executive Order supporting the advancement of novel treatments for neurological and mental health disorders.
The Company believes the Executive Order represents an important step toward enabling scientific research in areas that have historically been difficult to study due to regulatory constraints. Lobe views this action as a meaningful shift toward allowing compounds to be

Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders

Thu, 23 Apr 2026 08:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, welcomes the recent White House Executive Order supporting the advancement of novel treatments for neurological and mental health disorders.
The Company believes the Executive Order represents an important step toward enabling scientific research in areas that have historically been difficult to study due to regulatory constraints. Lobe views this action as a meaningful shift toward allowing compounds to be

Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services

Tue, 21 Apr 2026 06:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs, is pleased to announce that it has engaged Massive Intelligence Pty Ltd ("Massive Intelligence") to provide investor relations and corporate communications services.
Pursuant to an engagement letter dated April 15^th 2026, the Company has retained Massive Intelligence for an initial term of three (3) months, commencing April 15, 2026, with the option to renew for a further

Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services

Tue, 21 Apr 2026 06:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs, is pleased to announce that it has engaged Massive Intelligence Pty Ltd ("Massive Intelligence") to provide investor relations and corporate communications services.
Pursuant to an engagement letter dated April 15^th 2026, the Company has retained Massive Intelligence for an initial term of three (3) months, commencing April 15, 2026, with the option to renew for a further

Lobe Sciences closes $950,000 private placement for drug development

Mon, 20 Apr 2026 06:04:36 -0400

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) completed a non-brokered private placement offering of 14,615,384 common shares at $0.065 per share, raising approximately $950,000 in gross proceeds.

The biopharmaceutical company plans to use the funds for working capital and general corporate purposes, with a portion directed toward advancing its S-100 drug candidate for sickle cell disease treatment. Some proceeds will support its subsidiary, Applied Lipid Technologies, Inc., in developing the S-100 program toward human clinical trials.

The company stated it has obtained the active pharmaceutical ingredient required for the studies, allowing the program to proceed. Securities issued in the private placement are subject to a

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update

Mon, 20 Apr 2026 06:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce the closing of its previously announced non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement").
The Company intends to use the proceeds of the Private Placement for working capital and general corporate

Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update

Mon, 20 Apr 2026 06:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce the closing of its previously announced non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement").
The Company intends to use the proceeds of the Private Placement for working capital and general corporate

Lobe Sciences announces $950,000 private placement offering

Fri, 10 Apr 2026 20:00:12 -0400

Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) announced a non-brokered private placement offering of 14,615,384 common shares at $0.065 per share for aggregate gross proceeds of approximately $950,000.

The biopharmaceutical company stated it intends to use the net proceeds to fund working capital and general corporate expenses.

The private placement remains subject to receipt of regulatory approvals, including exchange acceptance. Securities issued will be subject to a four-month hold period from the closing date under Canadian securities laws.

Lobe Sciences operates through subsidiaries including a majority interest in Cynaptec Pharmaceuticals, Inc. and wholly owned subsidiary Applied Lipid Technologies Inc. Cynaptec is developing therapies for neurological and

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Fri, 10 Apr 2026 20:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce a non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement").
The Company intends to use the net proceeds of the Private Placement to fund working capital and general corporate expenses.
The Private Placement remains

Lobe Sciences Ltd. Announces Non-Brokered Private Placement

Fri, 10 Apr 2026 20:00:00 -0400

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
VANCOUVER, BC / ACCESS Newswire / April 10, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is pleased to announce a non-brokered private placement offering of 14,615,384 common shares in the capital of the Company ("Common Shares") at a price of $0.065 per Common Share, for aggregate gross proceeds of approximately $950,000 (the "Private Placement").
The Company intends to use the net proceeds of the Private Placement to fund working capital and general corporate expenses.
The Private Placement remains

Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update

Wed, 25 Mar 2026 08:20:00 -0400

Liabilities reduced 81%, from $2.35M to $0.44M
Cash increased more than 24x, from $0.24M to $5.99M
Net working capital improved by $6.1M, from ($2.01M) to $4.05M
Outstanding warrants reduced by ~70%, from 43M to 13M
VANCOUVER, BC / ACCESS Newswire / March 25, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) today provided a strategic and financial update highlighting significant improvements in its financial position since August 31, 2024, following a change in management.
Since fiscal year-end 2024, the Company has materially strengthened its balance sheet and capital structure. Convertible debt and other liabilities were

Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update

Wed, 25 Mar 2026 08:20:00 -0400

Liabilities reduced 81%, from $2.35M to $0.44M
Cash increased more than 24x, from $0.24M to $5.99M
Net working capital improved by $6.1M, from ($2.01M) to $4.05M
Outstanding warrants reduced by ~70%, from 43M to 13M
VANCOUVER, BC / ACCESS Newswire / March 25, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) today provided a strategic and financial update highlighting significant improvements in its financial position since August 31, 2024, following a change in management.
Since fiscal year-end 2024, the Company has materially strengthened its balance sheet and capital structure. Convertible debt and other liabilities were

Lobe Sciences names Mirza Rahimani as chief financial officer

Mon, 09 Mar 2026 00:00:12 -0400

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (Frankfurt: LOBE) appointed Mirza Rahimani as chief financial officer effective March 2, 2026, according to a company statement.

Rahimani, a chartered professional accountant, has been providing financial advisory services to the Vancouver-based biopharmaceutical company since December 1, 2025. He replaces Yong Yao, who served as CFO through an arrangement with Century Biolabs Inc.

The new CFO brings over 15 years of experience in accounting, financial reporting, corporate governance, and corporate development. His background includes supporting companies through debt and equity financings, mergers and acquisitions, and public company compliance requirements across life sciences, mining, and technology

Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer

Mon, 09 Mar 2026 00:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs. Lobe is pleased to announce the promotion of Mr. Mirza Rahimani to Chief Financial Officer, effective March 2, 2026. Mr. Rahimani has been working with the Company since December 1, 2025, providing financial advisory services to management and the Board of Directors, and is now assuming the role of

Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer

Mon, 09 Mar 2026 00:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs. Lobe is pleased to announce the promotion of Mr. Mirza Rahimani to Chief Financial Officer, effective March 2, 2026. Mr. Rahimani has been working with the Company since December 1, 2025, providing financial advisory services to management and the Board of Directors, and is now assuming the role of

Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences

Thu, 05 Mar 2026 07:40:00 -0400

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs.
The Company announces that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be in Miami, Florida during the upcoming Jefferies and Leerink Healthcare Conferences and will be available for meetings with investors, pharmaceutical companies, and organizations interested in learning more about the Company and its programs.
Lobe acquires preclinical

Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences

Thu, 05 Mar 2026 07:40:00 -0400

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with principal executive offices in Florida. The Company identifies and advances therapeutic programs addressing significant unmet medical needs.
The Company announces that its Chief Executive Officer, Dr. Frederick D. Sancilio, will be in Miami, Florida during the upcoming Jefferies and Leerink Healthcare Conferences and will be available for meetings with investors, pharmaceutical companies, and organizations interested in learning more about the Company and its programs.
Lobe acquires preclinical

Lobe Sciences Reports First Quarter 2026 Results and Highlights

Tue, 03 Feb 2026 07:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first quarter of fiscal 2026 ended November 30, 2025 (Q1:2026) and provided an update on operational progress for the quarter.
"During the first quarter of fiscal 2026, Lobe meaningfully accelerated its research and development activities, with R&D expenditures increasing to just under $1 million as we advanced our core programs through Cynaptec Pharmaceuticals, Inc.," said Dr. Fred

Lobe Sciences Reports First Quarter 2026 Results and Highlights

Tue, 03 Feb 2026 07:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first quarter of fiscal 2026 ended November 30, 2025 (Q1:2026) and provided an update on operational progress for the quarter.
"During the first quarter of fiscal 2026, Lobe meaningfully accelerated its research and development activities, with R&D expenditures increasing to just under $1 million as we advanced our core programs through Cynaptec Pharmaceuticals, Inc.," said Dr. Fred